Krystal Biotech, Inc. announced on February 28, 2025, that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive recommendation for the European Commission to approve VYJUVEK (beremagene geperpavec-svdt) for treating wounds in patients with dystrophic epidermolysis bullosa.

The announcement was made through a press release, which is included as Exhibit 99.1 in the company's filing. This information is not considered "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated into any registration statement or SEC filing unless explicitly stated.